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Abstract
Background: In France, it is estimated that 24% of HIV-infected patients are also infected with HCV. Longitudinal
studies addressing clinical and public health questions related to HIV-HCV co-infection (HIV-HCV clinical progression
and its determinants including genetic dimension, patients’ experience with these two diseases and their
treatments) are limited. The ANRS CO 13 HEPAVIH cohort was set up to explore these critical questions.
To describe the cohort aims and organization, monitoring and data collection procedures, baseline characteristics,
as well as follow-up findings to date.
Methods: Inclusion criteria in the cohort were: age > 18 years, HIV-1 infection, chronic hepatitis C virus (HCV)
infection or sustained response to HCV treatment. A standardized medical questionnaire collecting socio-
demographic, clinical, biological, therapeutic, histological, ultrasound and endoscopic data is administered at
enrolment, then every six months for cirrhotic patients or yearly for non-cirrhotic patients. Also, a self-administered
questionnaire documenting socio-behavioral data and adherence to HIV and/or HCV treatments is administered at
enrolment and yearly thereafter.
Results: A total of 1,175 patients were included from January 2006 to December 2008. Their median age at
enrolment was 45 years and 70.2% were male. The median CD4 cell count was 442 (IQR: 304-633) cells/μl and HIV
RNA plasma viral load was undetectable in 68.8%. Most participants (71.6%) were on HAART. Among the 1,048
HIV-HCV chronically co-infected patients, HCV genotype 1 was predominant (56%) and cirrhosis was present in
25%. As of January, 2010, after a median follow-up of 16.7 months (IQR: 11.3-25.3), 13 new cases of
decompensated cirrhosis, nine hepatocellular carcinomas and 20 HCV-related deaths were reported, resulting in a
cumulative HCV-related severe event rate of 1.9/100 person-years (95% CI: 1.3-2.5). The rate of HCV-related severe
events was higher in cirrhotic patients and those with a low CD4 cells count, but did not differ according to sex,
age, alcohol consumption, CDC clinical stage or HCV status.
Conclusion: The ANRS CO 13 HEPAVIH is a nation-wide cohort using a large network of HIV treatment, infectious
diseases and internal medicine clinics in France, and thus is highly representative of the French population living
with these two viruses and in care.
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Hepatitis C virus (HCV) infection is common among
the population living with HIV. In France, it is estimated
that 24% of HIV-infected patients are also infected with
HCV [1]. There is evidence that HIV negatively affects
the natural history of HCV infection, with an acceler-
ated progression of HCV-related liver disease towards
cirrhosis, decompensated liver disease or hepatocellular
carcinoma [2-4]. In contrast, there are conflicting data
about the impact of HCV infection on the course of
HIV disease [5-7].
Since the advent of highly active antiretroviral therapy
(HAART), which inhibits HIV replication and thus
enables patients to reach and sustain an effective
immune response, the mortality due to opportunistic
infections in HIV-infected patients has been drastically
reduced. As a consequence, chronic liver disease has
emerged as a major cause of morbidity and mortality
among HIV-infected individuals [8,9]. In addition, the
risk of hepatotoxicity linked to antiretroviral drugs and
alcohol abuse is increased in subjects with underlying
HCV infection [10].
While the use of pegylated interferon and ribavirin has
increased the chances of clearing HCV infection mainly
in patients presenting HCV genotypes 2 or 3 [11,12],
this treatment has also been shown to significantly
increase the burden of perceived side effects in patients
receiving HAART [13]. This is of utmost importance as
anti-HCV treatment and HAART require sustained high
levels of adherence in order to be effective.
To date, longitudinal studies on factors associated to
clinical progression of HIV-HCV co-infection, as well as
those related to patients’ experience with these two dis-
eases and their treatments, are limited [14-17].
Within this framework, the French National Agency
for Research on AIDS and Viral hepatitis (ANRS) CO
13 HEPAVIH collaboration initiated in 2005 a closed,
prospective, hospital-based cohort to address clinical
and public health issues around HIV-HCV co-infection,
which are summarized in the main objectives of the
cohort, as follows:
1) In the short-term (1-2 years after end of enrol-
ment): a) to describe HIV-HCV co-infection in
France and its management, including socio-beha-
vioral, diagnostic and therapeutic aspects, b) to vali-
date the accuracy of non-invasive methods for
assessing liver fibrosis;
2) In the mid-term (3-4 years): a) to study the
impact of HCV treatment on the clinical and
immuno-virological response of HIV, b) to study the
pharmacokinetics of antiretroviral drugs and anti-
HCV drugs according to histological liver disease
stage, and interactions between antiretroviral and
anti-HCV drugs, c) to identify physicians’ and
patients’ barriers to access to HCV treatment and
adherence to HIV or HCV treatments;
3) In a longer-term (5 years and beyond): a) to
describe the course of HIV-HCV co-infection and to
assess the role of factors such as clinical characteris-
tics and behaviors, genetics, exposure to HCV treat-
ment, HIV immuno-virolological status, HIV clinical
events and HAART use, on the occurrence of a
decompensated liver disease or hepatocellular carci-
noma, b) to study the impact of antiretroviral drugs
on the progression of liver fibrosis, c) to identify pre-
dictors of patients’ health-related quality of life and
perceived side effects and their evolution.
The aim of this article is to describe this ongoing
cohort, the characteristics of patients at enrolment as
well as the main follow-up achievements to date.
Methods
Inclusion criteria
Consecutive patients seen in 17 hospital wards between
January, 2006 and December, 2008 and who fulfilled the
f o l l o w i n gc r i t e r i aw e r ee n r o l l e di nt h eA N R SC O1 3
HEPAVIH cohort: aged 18 years or more, HIV-1/HCV
chronically co-infected as confirmed by a positive HIV
antibody test and an HCV RNA assay (regardless of the
clinical stage, gender or transmission group), written
informed consent.
In addition to these chronically co-infected patients,
HIV/HCV co-infected patients who had cleared their
HCV after a successful anti-HCV therapy, as evaluated
by a negative HCV RNA six months after the end of
anti-HCV treatment could be included. Thus, at their
enrolment, these patients were characterized as HCV
sustained responders.
Patients on HCV treatment at enrolment, with unde-
tectable HCV-RNA but not yet classified as sustained
responders were included in the cohort at the end of
their treatment phase.
Schedule of follow-up
The schedule of follow-up visits is based on clinical
practice as recommended by the European consensus
conferences on hepatitis C, that is every six months for
cirrhotic patients and every year for non-cirrhotic
patients [18-20]. Five specific additional visits are sched-
uled when anti-HCV treatment is initiated (baseline
visit, then at month 1, 3, at the end of treatment and six
months after the end of treatment).
A patient self-administered questionnaire is scheduled
at enrolment and yearly thereafter.
Loko et al. BMC Infectious Diseases 2010, 10:303
http://www.biomedcentral.com/1471-2334/10/303
Page 2 of 11Data collection
A standardized medical questionnaire is completed by
physicians at each clinical visit. Patients also use self-
administered questionnaires.
Clinical and histological outcomes
Patients have a regular physical examination. The results
of liver biopsy (LB), whenever available, are documented
and graded with the Metavir system. In all cases, a sys-
tematic assessment of liver fibrosis is also recommended
using non-invasive methods (FibroTest
™ and/or FibroS-
can
™) [21,22]. FibroScan cut-offs used for the conversion
in the Metavir score are: F0-F1: <7.1 Kpa, F2: 7.1-9.5
Kpa, F3: 9.5-12.5 Kpa, F4: ≥12.5 Kpa [23]. Given the dis-
cordances between liver biopsy results and those of non-
invasive methods, cirrhosis is diagnosed based on a hier-
archical algorithm (Figure 1). This algorithm considers
first the result of LB (F4 in the METAVIR system), then
the presence of indirect clinical signs of cirrhosis
(ascites, esophageal varices with or without bleeding,
hepatic encephalopathy), followed by the FibroScan
™
result (with an elasticity value >12.5 KPa), and lastly the
result of FibroTest
™ (F4 in the METAVIR system). A
final confirmation of the diagnosis obtained with this
a l g o r i t h mi sm a d eb yt h ep h y s i c i a ni nc h a r g eo ft h e
patient. The quality criteria of LB (at least six portal
tracts), FibroScan
™ (success rate ≥60% or an interquartile
range [IQR] less than 30% of the median liver stiffness
measurement [LSM] value) and FibroTest
™ (absence of
atazanavir or indinavir-related hyperbilirubinemia) are
taken into consideration when using the algorithm.
An ultrasound examination is performed to assess
possible complications of the liver disease. In case of
suspected or diagnosed cirrhosis, endoscopic examina-
tion is also prescribed.
All these data are collected at enrolment and yearly
(every six months for cirrhotic patients) and are com-
bined to define different indicators of HCV disease
progression.
Moreover, data on mortality, HIV- and HCV-related
clinical events with special focus on the end-stage liver
disease and hepatocellular carcinoma, access to HCV
treatment, and responses to anti-HCV and HIV treat-
ments are also studied as outcomes.
Socio-behavioral outcomes
Together with clinical outcomes, adherence to HIV or
HCV treatments or patients’ quality of life as expressed
by the WHO-QOL (World Health Organization Quality
Of Life for HIV) [24] and the fatigue impact scales are
investigated.
Exposure factors or potential predictors of outcomes
Clinical and biological variables are studied as potential
predictors of HCV progression.
Presence of lipodystrophy is considered when a lipoa-
trophy or a lipohypertrophy is identified, whatever the
anatomical site.
Blood tests performed at enrolment and during fol-
low-up cover aspects of general health: haemoglobin
and platelet count, biological markers of hepatitis C
virus infection, markers indicating past or current
infection with hepatitis B virus and parameters indica-
tive of the progression of HIV infection (CD4 cells
count, HIV plasma RNA). Other biological tests such
as liver function tests, total cholesterol, HDL and LDL-
cholesterol, triglycerides, creatinin, glycemia, insuline-
mia, lactates, lipase, apolipoprotein A1, haptoglobin,
a2-macroglobulin, cryoglobulin and complement com-
ponents (CH50, C4) are also performed at enrolment
and during follow-up. Insulin resistance (IR) is mea-
sured using the homeostasis model assessment of IR
(HOMA) [25].
Patients’ socio-demographic and psychosocial charac-
teristics, alcohol and substance use, perceptions about
treatments and their efficacy, use of psychotropic medi-
cations or substitution treatments, self-reported symp-
toms, depressive symptoms (CES-D scale [Center for
Epidemiologic Studies Depression Scale]) [26] and anger
(STAXI II scale [State-Trait Anger Expression Inven-
tory]) are used as potential explanatory variables for
clinical and socio-behavioral outcomes. Physicians’
socio-demographic characteristics and data on their pro-
fessional experience, their opinion about their patients’
current drug and alcohol use as well as their perception
of the patients’ adherence to scheduled visits and treat-
ment(s) are also used as potential explanatory variables
for clinical and socio-behavioral outcomes.
Blood samples (plasma, serum and whole blood) are
collected every year, as well as during anti-HCV treat-
ment, to be stored centrally.
Data management
Clinical and biological questionnaires are collected and
centralized at the INSERM U897 Epidemiology centre in
Bordeaux, France, where they are checked for accuracy
and completeness. Self-administered questionnaires are
sent to the INSERM U912 Social Sciences Unit in Mar-
seille where they are validated and then double-entered
in a specific database. Standardized procedures are used
to compute the scores of the administered scales
(WHO-QOL, CES-D, STAXI-II, FIS). A unique database
merging clinical, socio-behavioral and psychosocial data
is built every six months for all statistical analyses.
The database used for the current manuscript
included information recorded at enrolment as well as
during follow-up up to January 2010.
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Continuous variables are described by their median
value and interquartile range (IQR); categorical variables
are described as percentages.
Event rates are compared using a Poisson regression
analysis. Survival curves are compared using the Log-
rank test.
All statistical tests are two-sided, with a type I error
of 5%.
Ethical aspects
The study was designed and performed in accordance
with the Declaration of Helsinki and was approved by the
ethics committee of Cochin university hospital in Paris.
Results
Patients’ characteristics
From January 2006, until December 2008 (enrolment
period), a total of 1,175 patients were enrolled in the
Figure 1 Algorithm for assessing cirrhosis, ANRS CO 13 HEPAVIH cohort of HIV-HCV co-infected patients.
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and 127 HCV sustained responders.
Table 1 summarizes the baseline characteristics of the
1,175 enrolled patients and Tables 2 and 3 provide
further HIV and HCV-related characteristics. Their
median age was 45 years (IQR: 42-48 years) and most
participants were males (70.2%).The median baseline
CD4 absolute count was 442 cells/μl (IQR: 304-633) and
HIV RNA plasma viral load was undetectable in 68.8%
of the patients.
For HIV-HCV chronically co-infected patients, the
median time elapsed since the diagnosis of HCV infec-
tion was 10 years (IQR: 6-14) and the main source of
contamination was intravenous drug exposure. HCV
genotype 1 was predominant (56%). The median HCV
RNA plasma viral load was 6.2 logUI/ml (IQR: 5.7-6.5).
Evaluation of liver fibrosis at enrolment (+/- one year),
with LB, FibroTest
™ or FibroScan
™ was available for 196,
732 and 824 patients, respectively. In patients for whom
the three examinations were available (N = 78), the dis-
tribution of fibrosis stages was different depending on
the test used. The proportion of patients with F3 or F4
stage was higher with FibroTest
™ (46%) than with
FibroScan
™ (30%) or LB (27%), whereas the proportion
of patients with F0-F1 stage was higher with FibroScan
™
(52%), compared to FibroTest
™ (41%) and LB (38%) (Fig-
ure 2). Twenty-five percent of patients were documen-
ted as cirrhotic at their enrolment, using the study
algorithm of cirrhosis and confirmation of diagnosis by
physicians.
At enrolment, 71.6% of the patients were receiving
HAART, for a median duration of 9.3 years (IQR: 4.6-
12.1). The most frequent drug combination was two
nucleoside reverse transcriptase inhibitors (NRTI) and
one ritonavir-boosted protease inhibitor (PI), represent-
ing 57.6% of the treated patients whereas the combina-
tion of two NRTIs and one non nucleoside reverse
transcriptase inhibitor (NNRTI) represented 17.2% of
treated patients (Table 2).
With regards to anti-HCV therapy, 371 (35.4%) HIV-
HCV chronically infected patients had been treated at
l e a s to n c ef o rH C Vb e f o r ee n r o l m e n ti nt h ec o h o r t ,
with the following regimens: interferon alone: n = 33,
interferon + ribavirin: n = 65, pegylated interferon +
ribavirin: n = 273 (Table 3).
Since enrolment up to January, 2010, 238 patients
received pegylated interferon plus ribavirin therapy: 74
among those previously treated patients and 164 among
Table 1 Baseline socio-demographic, clinical and biological characteristics of patients included in the ANRS CO 13
HEPAVIH cohort of HIV-HCV co-infected patients, France, 2006-2008
Total N=1175 HCV chronically infected patients
N=1048
HCV sustained responders
N=127
Age (years), median (IQR) 45 (42-48) 45 (42-48) 46 (43-49)
Male gender, N (%) 825 (70.2) 735 (70.1) 90 (70.9)
BMI (kg/m
2), median (IQR) 21.6 (19.7-24.1) 21.6 (19.7-24.1) 22.0 (20.1-24.3)
High school certificate, N (%) 302(34) 260 (33) 42 (42)
Employment, N (%) 481 (49) 423 (48) 58 (52)
Quality of life (WHOQOL), median (IQR)
Physical 14 (11-16) 14 (11-16) 14 (11-16)
Psychological 14 (12-17) 14 (12-17) 14 (12-16)
Level of independence 14 (11-17) 14 (11-17) 14 (10-17)
Social relationship 14 (12-17) 14 (11-17) 15 (12-17)
Environment 15 (13-17) 15 (12-17) 15 (14-17)
Spirituality/religion 14 (12-16) 14 (12-16) 14 (12-17)
Alcohol consumption (gr/day): >20 (women) or >30 (men),
N (%)
120 (10.7) 109 (10.9) 11 (8.9)
Daily cocaine use in the last month, N (%) 136 (14) 123 (15) 13 (13)
Depressive symptoms (CES-D>17 for men, CES-D>23 for
women), N (%)
379 (41) 343 (41) 36 (34)
HOMA, median (IQR) 2.0 (1.3-3.4) 2.1 (1.3-3.5) 2.1 (1.4-3.1)
Lipodystrophy, N (%) 635 (54.0) 560 (53.4) 75 (59.1)
Diabetes, N (%) 69 (5.9) 62 (5.9) 7 (5.5)
ALT (x normal), median (IQR) 1.2 (0.8-2.0) 1.3 (0.9-2.1) 0.6 (0.4-0.8)
AST (x normal), median (IQR) 1.1 (0.8-1.8) 1.2 (0.8-1.9) 0.7 (0.5-0.9)
Hepatitis B surface antigen positive, N (%) 22 (2.0) 20 (2.0) 2 (1.7)
BMI: body mass index; HOMA : homeostasis model assessment of insulin-resistance; IQR: interquartile range; CES-D : Center for Epidemiologic Studies Depression
scale; WHO-QOL : World Health Organization Quality Of Life for HIV.
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co-infected patients, France, 2006-2008
Total N=1175 HCV chronically infected patients
N=1048
Sustained HCV responders
N=127
CDC clinical stage: C, N (%) 324 (27.8) 300 (28.9) 24 (19.2)
Years since HIV diagnosis, median (IQR) 18 (13-20) 18 (13-20) 18 (14-21)
HIV transmission category, N (%)
Intravenous drug use 724 (62.0) 651 (62.5) 73 (57.9)
Sexual 318 (27.2) 282 (27.1) 36 (28.6)
Transfusion 85 (7.3) 73 (7.0) 12 (9.5)
Other or unknown 40 (3.4) 35 (3.4) 5 (4.0)
Nadir CD4 (/μl), median (IQR) 150 (66-248) 146 (65-247) 169 (96-251)
CD4 cells count at initiation of antiretroviral treatment (/μl),
median (IQR)
242 (139-357) 240 (132-354) 256 (191-396)
CD4 cells count at baseline (/μl), median (IQR) 442 (304-633) 438 (300-630) 492 (345-662)
CD4 cells count at baseline (/μl), N (%)
<200 130 (11.2) 126 (12.2) 4 (3.1)
200-350 251 (21.6) 223 (21.6) 28 (22.0)
351-500 301 (25.9) 269 (26.1) 32 (25.2)
>500 479 (41.3) 416 (40.2) 63 (49.6)
Patients with <40 HIV RNA copies/ml, N (%) 797 (68.8) 702 (68.1) 95 (74.8)
Patients receiving HAART, N (%) 841 (71.6) 750 (71.6) 91 (71.6)
2 NRTI + 1 PI 613 (52.2) 552 (52.7) 61 (48.0)
2 NRTI + 1 NNRTI 183 (15.6) 158 (15.1) 25 (19.7)
1 NRTI + 1 NNRTI + 1 PI 45 (3.8) 40 (3.8) 5 (3.9)
Regimen including raltegravir 26 (2.2) 23 (2.2) 3 (2.4)
PI: protease inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; IQR: interquartile range;HAART: highly
active antiretroviral therapy.
Table 3 Baseline characteristics of HCV infection of patients included in the ANRS CO 13 HEPAVIH cohort of HIV-HCV
co-infected patients, France, 2006-2008
Total
N=1175
HCV chronically infected patients
N=1048
Sustained HCV responders
N=127
Years since HCV diagnosis, median (IQR) - 10 (6-14) -
HCV genotype, N (%) - -
1 577 (56.0)
2 39 (3.8)
3 187 (18.1)
4 225 (21.8)
5 or other 3 (0.3)
HCV plasma RNA (Log10) (IU/ML), median (IQR) - 6.2 (5.7-6.5) -
Past anti HCV therapy, N (%)
Interferon alone 40 (3.4) 33 (3.1) 7 (5.5)
Interferon+ ribavirin 93 (7.9) 65 (6.2) 28 (22)
Pegylated interferon plus ribavirin 365 (31.1) 273 (26.0) 92 (72.5)
Cirrhosis*, N (%) 255 (25.2) 229 (25.0) 26 (26.8)
Documented decompensated liver disease,
N (%)
32 (2.7) 27 (2.6) 5 (3.9)
* according to the study algorithm of cirrhosis (see Figure1).
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HIV-HCV chronically infected patients (51%) had access
at least once to anti-HCV therapy up to the closing date
of the present report.
Among the 238 patients treated for HCV infection
since enrolment in the cohort, 127 (53%) so far, had
available data on sustained virological response (SVR).
Overall, 40 (31.5%) achieved sustained virological
response. The rate of HCV clearance was 34% in treat-
ment-naïve patients and 27% in the previously treated
group. When stratified according to HCV genotypes, the
rate of SVR was 20% in patients with genotype 1, 62%
in patients with genotype 2 or 3 and 36% in patients
with genotype 4.
Main clinical events occurring since enrolment and time-
to-event analyses
Overall, the cumulative follow-up duration, calculated
between the date of enrolment of each patient and
the last follow-up visit, the date of consent removal
or the date of death was 1,775 person-years (P-A).
The median duration of follow-up was 16.7 months
(IQR: 11.3-25.3).
Up to January 2010, 13 new cases of decompensated
cirrhosis (presence of ascites, varices bleeding, or hepatic
encephalopathy) were diagnosed, all in the HIV-HCV
chronically infected patients. Nine new cases of hepato-
cellular carcinoma (six in HIV-HCV chronically infected
patients and three in sustained responders) were
reported in the cohort. Forty-nine deaths (47 in HIV-
HCV chronically infected patients and two in sustained
responders) occurred and 20 (41%) of them were cate-
gorized as attributable to HCV infection.
A time-to-event analysis was performed to estimate
the incidence since enrolment, of HCV-related severe
events, defined as the occurrence of a first hepatic
decompensation (presence of ascites, varices bleeding, or
hepatic encephalopathy), hepatocellular carcinoma or
HCV-related death. As of January, 2010, a total of 33
HCV-related severe events (30 in HIV-HCV chronically
infected patients and three in sustained responders)
were reported, resulting in a cumulative HCV-related
severe event rate of 1.9/100P-A (95% CI: 1.3-2.5). When
stratified according to cirrhosis status, the rate of HCV
severe events was higher for cirrhotic patients (6.9/
100P-A) than for non-cirrhotic patients (0.35/100P-A)
(p < 10
-4) (Figure 3). The rate of HCV-related severe
events was also higher in patient with a baseline CD4
absolute count <200/μl than in those with a CD4 count
above this threshold (5.5 vs 1.4/100P-A; p = 0.002). The
rate of HCV-related severe events did not differ accord-
ing to other factors such as sex (2.1 in male vs 1.4/
100P-A in female; p = 0.32), age (1.7 in patients aged 45
years or less vs 2.1/100P-A in others; p = 0.55), alcohol
c o n s u m p t i o n( 2 . 9i fa l c o h ol consumption >20 gr/day
[women] or >30 gr/day [men] vs 1.8/100P-A in others;
p = 0.36), CDC clinical stage (2.8 in patients with CDC
clinical stage C vs 1.6/100P-A in others; p = 0.14) or
HCV status (1.9 in HIV-HCV chronically infected
patients vs 1.8/100P-A in HCV sustained responders;
p = 0.88).
Given the algorithm used to identify cirrhotic patients,
the performance of this algorithm, as well as of each
contributing test (LB, FibroScan, FibroTest) on the
occurrence of HCV-related severe events was evaluated.
T h en e g a t i v ep r e d i c t i v ev a l u e( N P V )o ft h ea l g o r i t h m
Figure 2 Prevalence of liver fibrosis and its 95% confidence interval at baseline (+/- 1 year) in patients with concomitant results of
liver biopsy, FibroScan
™ and FibroTest
™, and regardless of HCV status (N = 78), ANRS CO 13 HEPAVIH cohort of HIV-HCV co-infected
patients, France, 2006-2008.
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absence of HCV-related severe events was good
(98-99%). However, the positive predictive values were
low: 12.5% for the algorithm and 7.4 to 10.3% for the
individual tests (Table 4).
Socio-behavioral findings
Using data from the medical and self-administrated ques-
tionnaires, we showed that successful treatment for
depression may reduce the negative impact that fatigue
has on cognitive, physical and social functioning of HIV-
HCV co-infected patients. Indeed, this analysis published
elsewhere has demonstrated that the impact of fatigue on
daily functioning in HIV-HCV co-infected patients is
determined by two dimensions; on one hand, psychoso-
cial and demographic factors as expressed by the number
of discomfort side effects, employment status and gender
(women), on the other hand, clinical factors related to
the severity of HIV disease, choice of antiretroviral drugs,
depression and its management [27].
Discussion
The ANRS CO 13 HEPAVIH cohort has been
assembled through a unique nation-wide collaboration
of HIV treatment, infectious diseases, internal medicine
and hepatology centres in France. This article provides
Figure 3 Probability of remaining free of HCV-related severe event*, according to cirrhosis status, ANRS CO 13 HEPAVIH cohort of
HIV-HCV co-infected patients. Bars represent confidence intervals at 6, 12 and 18 months.
Table 4 Predictive values of the cirrhosis algorithm and of liver biopsy, FibroScan and FibroTest for the prediction of
HCV-related severe events occurrence, ANRS CO 13 HEPAVIH cohort of HIV-HCV co-infected patients
HCV-related severe events
a
Absence (n) Presence (n) PPV (%) NPV (%)
Algorithm* N=987 Absence of cirrhosis 752 4 12.5 99.5
Presence of cirrhosis 203 29
Liver Biopsy N=192 Metavir < F4 161 2 10.3 98.8
Metavir F4 26 3
FibroScan N=806 <12.5KPa 653 4 7.4 99.4
≤ 12.5 KPa 138 11
FibroTest N=718 Metavir < F4 528 7 8.2 98.7
Metavir F4 168 15
* See definition in Methods section; PPV: positive predictive value; NPV negative predictive value.
a HCV-related severe events: ascites, varices bleeding, hepatic encephalopathy, hepatocellular carcinoma or HCV-related death.
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toring and data collection procedures, the baseline char-
acteristics of patients, as well as the main follow-up
findings to date.
A total of 1,175 patients were enrolled in the cohort,
including 1,048 HIV-HCV chronically co-infected
patients. Compared to results of a national cross-sec-
tional survey on French HIV-HCV co-infected patients
performed in 2001 [28], the ANRS CO 13 HEPAVIH
HIV-HCV co-infected patients tended to be older at
enrolment (mean age 45 vs. 39 years). They were also
less often in CDC clinical stage C (28% vs. 34%) [29]
and had a higher CD4 cells count (CD4 > 500 cells/μl
:41% vs. 30%) than patients surveyed in 2001. These dif-
ferences could be due to an improved control of HIV
disease over time through the use of more effective anti-
retroviral treatment regimens. These differences were
also observed when our cohort was compared to cohorts
from other countries, such as the Swiss HIV cohort
(median age 35 years, median CD4 172/mm
3) [6]. How-
ever, our patients were comparable to those included in
a cross-sectional national study performed in 2006 in
France [30]. Also, the frequency of patients in our
cohort with histological cirrhosis was similar to that
reported in other studies [1,28].
HCV genotypes 1 and 4 were mostly observed in HIV-
HCV chronically co-infected patients (56% and 22%,
respectively), which was consistent with data from other
hospital-based cohorts in France and elsewhere in Eur-
ope [14,31,32]. This high prevalence of genotypes 1 and
4 in the HIV-HCV chronically co-infected patients of
our cohort could be due to the recruitment of relapsers
or non-responders to a previous course of HCV therapy.
Indeed, in those relapsers or non-responders, HCV gen-
otypes 1 and 4 are highly prevalent, contrary to HCV
genotypes 2 and 3 [11,33].
Fifty-one percent of HIV-HCV chronically infected
patients in the ANRS CO 13 HEPAVIH cohort had
access at least once to anti-HCV therapy. This propor-
tion was higher than in previous reports in France (with
only 31 to 45% of patients treated for HCV infection)
[1,28], suggesting an improvement in the management
of HIV-HCV patients over time. This relatively good
uptake of HCV therapy in our cohort also contrasted
with rates reported in HIV-HCV patients in Spain so far
(41%) and with low rates observed in studies conducted
in North America (6-33%) [32,34-36]. Differences in
patients’ characteristics and easy access to medication
(including free or cheap provision of drugs) may explain
at least partly these differences.
During follow-up, 33 HCV-related severe events
occurred after a median follow-up de 16.7 months. As
expected, the incidence of these events was higher in
cirrhotic patients, emphasizing the importance to
accurately diagnose cirrhosis in such patients. In our
cohort, an algorithm combining liver biopsy, Fibrotest
and Fibroscan was used to identify cirrhotic patients,
who are thus likely to benefit from a regular follow-up.
The negative predictive value of this algorithm for pre-
dicting the absence of HCV-related severe events was
good (99.5%). However its positive predictive value was
low (12.5%), probably due to the relatively short follow-
up duration in the cohort. Nevertheless, this algorithm
had higher predictive values than the individual tests for
the prediction of HCV-related severe events. This find-
ing suggests that the use of an algorithm could lead to
an acceptable rate of misclassification for cirrhosis, thus
allowing a better case management. The main limitation
of this algorithm is the quality criterion of liver biopsy
(at least six portal tracts) which may be insufficient to
accurately diagnose cirrhosis. However, only 196 (16.7%)
patients had a liver biopsy during the year preceding or
following inclusion in the cohort. In addition, given the
hierarchical dimension of this algorithm, it is likely that
patients inaccurately diagnosed by liver biopsy may then
be correctly diagnosed by the other tests, thus minimiz-
ing the difficulties of performing and interpreting liver
biopsy in such patients.
The participants enrolled in the ANRS CO 13 HEPA-
VIH cohort came from 17 clinical centres, representing
four regions of high prevalence for HCV infection in
France. Despite this relatively limited geographical dis-
tribution, our sample seemed comparable to other
national multicentric studies in France. Therefore, the
ANRS CO 13 HEPAVIH cohort mirrors the whole
French population living with HIV and HCV and cur-
rently in care, thus providing a good representativeness
of co-infection in real life situations.
The main strength of the ANRS CO 13 HEPAVIH
cohort is the combined longitudinal data collection of
clinical and socio-behavioral items that makes this
cohort unique in the field. This organization provides
not only the possibility to study risk factors of HCV
progression but also to monitor both patient’s response
and experience with treatment and to investigate the
multi-factorial reasons for non-treatment and also non-
response to treatment.
In addition, its structure allows the set-up of ad hoc
studies at different follow-up points in order to answer
future research questions, such as genetic determinants
of cirrhosis, HCV treatment response and tolerance to
new antiretroviral treatments.
The schedule of follow-up visits in the cohort is based
on recommended clinical practices [20], which facilitates
the adherence of physicians and participants to the pro-
ject and improves the management of patients.
One of the strengths of the cohort is also data collec-
tion, which is standardized, and includes all relevant
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blood samples are regularly collected and centralized for
planned and future studies (at enrolment, 92% of our
patients had frozen blood samples). Lastly, data are sys-
tematically monitored and centralized in a single
database.
The ANRS CO 13 HEPAVIH cohort however does
have certain weaknesses, including the limited geogra-
phical distribution of participating centres, the nonparti-
cipation of HIV-HCV patients from community-based
clinics or primary care centers (although an uncommon
feature of HIV-HCV care in France) and the fact that it
is a prevalent cohort with a potential for selection of
individuals with more severe disease and then at high
risk of developing the outcomes of interest shortly after
being recruited.
Patients lost to follow-up are of major concern in pro-
spective cohorts. This might bias findings if attrition is
linked to disease severity and/or death. To address this
possible source of bias, the participating clinics together
with the coordination centre have been providing sus-
tained efforts to actively look for the patients who have
not been seen for more than two years (10% of the over-
all cohort for the time being) and to encourage them to
attend at least one more a follow-up visit. Finally, an
information campaign has been performed, targeting
patients and health care providers to disseminate the
first study results and explain once again the importance
of this study component.
Conclusions
Prospectively designed large scale observational cohorts,
representative of specific populations such as HIV-HCV
co-infected patients, will be critical to address future
clinical and public health questions related to chronic
diseases of infectious origin. Nation-wide cohorts such
as the French ANRS CO 13 HEPAVIH cohort may con-
tribute to set the base for further broader collaborations
to explore rare outcomes and long term prognosis.
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